Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pyxis Oncology (PYXS) Cash from Financing Activities (2024 - 2025)

Pyxis Oncology (PYXS) has disclosed Cash from Financing Activities for 2 consecutive years, with $669000.0 as the latest value for Q4 2025.

  • Quarterly Cash from Financing Activities rose 1238.0% to $669000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.4 million through Dec 2025, down 96.01% year-over-year, with the annual reading at $594000.0 for FY2025, 99.0% down from the prior year.
  • Cash from Financing Activities for Q4 2025 was $669000.0 at Pyxis Oncology, up from -$8000.0 in the prior quarter.
  • The five-year high for Cash from Financing Activities was $57.5 million in Q1 2024, with the low at -$8000.0 in Q3 2025.